116 related articles for article (PubMed ID: 33156706)
1. Comment on Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens.
Jefri MY; Nelson LS
Clin Toxicol (Phila); 2021 Jan; 59(1):79-80. PubMed ID: 33156706
[No Abstract] [Full Text] [Related]
2. Authors' reply to Comment on Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens.
Purssell R; Godwin J; Moe J; Buxton J; Kestler A; Brubacher JR
Clin Toxicol (Phila); 2021 Jan; 59(1):80-81. PubMed ID: 33215939
[No Abstract] [Full Text] [Related]
3. Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study.
Purssell R; Godwin J; Moe J; Buxton J; Crabtree A; Kestler A; DeWitt C; Scheuermeyer F; Erdelyi S; Balshaw R; Rowe A; Cochrane CK; Ng B; Jiang A; Risi A; Ho V; Brubacher JR
Clin Toxicol (Phila); 2021 Jan; 59(1):38-46. PubMed ID: 32401548
[TBL] [Abstract][Full Text] [Related]
4. Articles You May Have Missed.
Adkins A; Trautman W
J Med Toxicol; 2023 Jan; 19(1):49-52. PubMed ID: 36301466
[No Abstract] [Full Text] [Related]
5. High-dose buprenorphine for treatment of high potency opioid use disorder.
Danilewitz M; McLean M
Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
[TBL] [Abstract][Full Text] [Related]
6. Ultrarapid opioid detoxification of two children with congenital heart disease.
Greenberg M
J Addict Dis; 2000; 19(4):53-8. PubMed ID: 11110064
[TBL] [Abstract][Full Text] [Related]
7. Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns.
Kienbaum P; Scherbaum N; Thürauf N; Michel MC; Gastpar M; Peters J
Crit Care Med; 2000 Apr; 28(4):969-76. PubMed ID: 10809268
[TBL] [Abstract][Full Text] [Related]
8. Naloxone-Induced Acute Opioid Withdrawal in a Stabilized Extended-Release Naltrexone-Treated Patient.
Spitzberg AJ; Urner EM; Wirshing WC
Prim Care Companion CNS Disord; 2020 Sep; 22(5):. PubMed ID: 32942347
[No Abstract] [Full Text] [Related]
9. Novel Oral Nanoparticle Formulation of Sustained Release Naloxone with Mild Withdrawal Symptoms in Mice.
Madison CA; Arora M; Kumar MNVR; Eitan S
ACS Chem Neurosci; 2020 Jul; 11(13):1955-1964. PubMed ID: 32491828
[TBL] [Abstract][Full Text] [Related]
10. Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice.
Zhang G; Wu X; Zhang YM; Liu H; Jiang Q; Pang G; Tao X; Dong L; Stackman RW
Neuropharmacology; 2016 Feb; 101():246-54. PubMed ID: 26432939
[TBL] [Abstract][Full Text] [Related]
11. Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
Lofwall MR; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2007 Oct; 194(3):381-93. PubMed ID: 17605004
[TBL] [Abstract][Full Text] [Related]
12. New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.
Sanders M; Jones S; Löwenstein O; Jansen JP; Miles H; Simpson K
Pain Med; 2015 Aug; 16(8):1540-50. PubMed ID: 26110375
[TBL] [Abstract][Full Text] [Related]
13. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
14. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
Walsh SL; Strain EC; Bigelow GE
Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
[TBL] [Abstract][Full Text] [Related]
16. Reversal of opioid overdose syndrome in morphine-dependent rats using buprenorphine.
Zamani N; Hassanian-Moghaddam H; Bayat AH; Haghparast A; Shadnia S; Rahimi M; Hashemi Demaneh B; Assar N
Toxicol Lett; 2015 Feb; 232(3):590-4. PubMed ID: 25510513
[TBL] [Abstract][Full Text] [Related]
17. Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control.
Chu LF; Rico T; Cornell E; Obasi H; Encisco EM; Vertelney H; Gamble JG; Crawford CW; Sun J; Clemenson A; Erlendson MJ; Okada R; Carroll I; Clark JD
Drug Alcohol Depend; 2018 Feb; 183():176-183. PubMed ID: 29278818
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
19. Comparing the safety and efficacy of intravenous naloxone administration in opioid-naive and opioid-tolerant hospitalized oncology patients.
Lee S; Tatla V; Buga S; Pon D
J Opioid Manag; 2022; 18(6):497-502. PubMed ID: 36523200
[TBL] [Abstract][Full Text] [Related]
20. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
[No Abstract] [Full Text] [Related]
[Next] [New Search]
